Nan Fung Group Holdings’s Kymera Therapeutics KYMR Stock Holding History

Nan Fung Group Holdings’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.54M	Hold	30,875	–	–	2.69%	11
2026 Q1	$2.57M	Hold	30,875	–	–	2.12%	12
2025 Q4	$2.4M	Hold	30,875	–	–	2.15%	15
2025 Q3	$1.75M	Hold	30,875	–	–	2.93%	13
2025 Q2	$1.35M	Hold	30,875	–	–	2.12%	13
2025 Q1	$845K	Hold	30,875	–	–	0.69%	25
2024 Q4	$1.24M	Buy	30,875 +20,000	+184%	+$903K	1.06%	24
2024 Q3	$515K	Hold	10,875	–	–	0.44%	30
2024 Q2	$325K	Hold	10,875	–	–	0.35%	31
2024 Q1	$437K	Buy	+10,875	New	+$389K	0.41%	34
2022 Q1	–	Sell	-4,960	Closed	-$315K	–	51
2021 Q4	$315K	Buy	+4,960	New	+$289K	0.09%	39

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Nan Fung Group Holdings's KYMR Position: Q2 2026 in Review

Nan Fung Group Holdings held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 30,875 shares worth $3.54M. The position accounts for 2.69% of the portfolio, ranked #11.

Nan Fung Group Holdings first reported a position in KYMR in Q4 2021 and has held it in 11 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Nan Fung Group Holdings held 30,875 shares of Kymera Therapeutics worth $3.54M as of Q2 2026.
Nan Fung Group Holdings left its Kymera Therapeutics share count unchanged in Q2 2026.
Kymera Therapeutics made up 2.69% of Nan Fung Group Holdings's portfolio in Q2 2026, its #11 holding.
Nan Fung Group Holdings first reported a position in Kymera Therapeutics in Q4 2021 and has held it in 11 quarters since.
276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Nan Fung Group Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.